Afternoon Coffee: 2nd Government Shutdown Unlikely, President Says; Tipalti Announces Growing Transactions, Staff

slasnyi/Adobe Stock

President Donald Trump said Tuesday that a second government shutdown likely won’t happen at Friday’s deadline despite him not being happy with plans for border security, CNBC reports.

"I don't think you're going to see a shutdown," he said.

This comes after lawmakers emerged from a meeting Monday night saying they had a deal in principle to fund the government past the deadline.

CNBC had these details about the deal:

“The measure would put about $1.4 billion toward physical border barriers, but not a wall as the president has demanded. It includes money for 55 new miles of bollard fencing (slates) on the U.S.-Mexico border.”

‘Aggressive Growth Period’

The global payables automation provider Tipalti on Tuesday announced two new hires and that the California-based firm has surpassed $6.5 billion in annual transactions.

“We’re excited to continue developing our strong team during this aggressive growth period,” said Chen Amit, CEO and co-founder of Tipalti, in a press release.

Todd McGuire was hired as GM of supplier success. A 20-plus-year veteran of the payments industry and consulting, he came from Worldpay, where he was the chief transformation officer for the U.S., the release said.

Perla Stoeckert is Tipalti’s new chief compliance officer, who has more than 15 years of experience in financial services with the likes of OFX, FXCM and Commonwealth Foreign Exchange (MoneyCorp), the release said. She has handled financial services around the globe.

A development from last fall also shows Tipalti’s growth, which was recognized by the firm making the 2018 Deloitte Technology Fast 500 list, ranking 279 and showing 304% fiscal year revenue growth from 2014-17.

Do Drug Prices Imperil USMCA?

The trade pact replacement to the NAFTA still needs congressional approval, and with Democrats taking over in the U.S. House, the USMCA is not a done deal.

And a new issue spells trouble — and it’s not related to manufacturing issues, cheap labor in Mexico or Canada’s protections of its industries. It’s drug prices, the Associated Press reports.

“As Democrats in Congress consider whether to back a revamped regional trade pact being pushed by President Donald Trump, they’re zeroing in on a new point of conflict: Drug prices. They contend that the new pact would force Americans to pay more for prescription drugs, and their argument has dimmed the outlook for one of Trump’s signature causes.”

Share on Procurious

Discuss this:

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.